ABCL · AbCellera Biologics Inc. · Documents

Feb 27

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $28.83M ▼ 24.2% Net loss $162.86M Diluted EPS -$0.55

Feb 27

Registration statement S-3ASR

Registration statement

Feb 18

Current report 8-K

Other events

Nov 4

Earnings call

Q3 2024 earnings call

Nov 4

Current report 8-K

Financial results, Regulation FD disclosure

Nov 4

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $6.51M ▼ 1.4% Net loss $51.11M Diluted EPS -$0.17

Aug 6

Earnings call

Q2 2024 earnings call

Aug 6

Current report 8-K

Financial results, Regulation FD disclosure

Aug 6

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $7.32M ▼ 27.2% Net loss $36.93M Diluted EPS -$0.13

Jun 13

Current report 8-K

Shareholder vote results

May 7

Earnings call

Q1 2024 earnings call

May 7

Current report 8-K

Financial results, Regulation FD disclosure

May 7

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $9.95M ▼ 18.4% Net loss $40.61M Diluted EPS -$0.14

Apr 29

Proxy statement DEF 14A

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEFA14A

Proxy statement

Feb 23

Current report 8-K Events of Feb 16

Director or officer change, or executive pay

Feb 20

Earnings call

Q4 2023 earnings call

Feb 20

Current report 8-K

Financial results, Regulation FD disclosure

Feb 20

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $38.03M ▼ 92.2% Net loss $146.4M Diluted EPS -$0.51

Nov 28

Current report 8-K

Other events

Nov 2

Earnings call

Q3 2023 earnings call

Nov 2

Current report 8-K

Financial results, Regulation FD disclosure

Nov 2

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $6.6M ▼ 93.5% Net loss $28.61M Diluted EPS -$0.10

Oct 13

Current report 8-K Events of Sep 18

Other events

Aug 3

Earnings call

Q2 2023 earnings call

Aug 3

Current report 8-K

Financial results, Regulation FD disclosure

Aug 3

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $10.06M ▼ 78.1% Net loss $30.53M Diluted EPS -$0.11

Jun 20

Current report 8-K Events of Jun 15

Shareholder vote results

May 24

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Other events

May 4

Earnings call

Q1 2023 earnings call

May 4

Current report 8-K

Financial results, Regulation FD disclosure

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $12.19M ▼ 96.1% Net loss $40.11M Diluted EPS -$0.14

Apr 28

Proxy statement DEF 14A

Proxy statement

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Mar 13

Current report 8-K Events of Mar 10

Regulation FD disclosure

Feb 21

Earnings call

Q4 2022 earnings call

Feb 21

Current report 8-K

Financial results, Regulation FD disclosure

Feb 21

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $485.42M ▲ 29.4% Net income $158.52M ▲ 3.3% Diluted EPS $0.50 ▲ 4.2%

Nov 8

Earnings call

Q3 2022 earnings call

Nov 8

Current report 8-K

Financial results, Regulation FD disclosure

Nov 8

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $101.38M ▲ 1740.6% Net income $26.62M Diluted EPS $0.08

Aug 9

Earnings call

Q2 2022 earnings call

Aug 9

Current report 8-K

Financial results, Regulation FD disclosure

Aug 9

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $45.92M ▲ 66.1% Net loss $6.79M Diluted EPS -$0.02

Jul 22

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2021

Jul 19

Current report 8-K Events of Jul 9

Director or officer change, or executive pay

Jul 6

Current report 8-K Events of Jun 29

Director or officer change, or executive pay

Jun 30

Current report 8-K Events of Jun 29

Regulation FD disclosure